A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

About the trial

Sponsor

Genmab (with AbbVie)

Tested

Epcoritamab (drug), Lenalidomide (drug), Ibrutinib (drug), Rituximab (drug), Cyclophosphamide (drug), Doxorubicin Hydrochloride [HCl] (drug), Prednisone (drug), Polatuzumab Vedotin (drug), CC-99282 (drug)

Dates

Started 2022-06-14; completion 2032-11

Results posted

Not yet

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purpose of this study is to assess the safety and tolerability of epcoritamab in combination with anti-neoplastic agents in adult participants with Non-Hodgkin lymphoma (NHL). Adverse events and change in disease activity will be assessed. Epcoritamab is an investigational drug being developed for the treatment of NHL. Study doctors put the participants in groups called treatment arms. The combination of epcoritamab with anti-neoplastic agents will be explored. Each treatment arm receives a different treatment combination depending on eligibility. Approxi…

From ClinicalTrials.gov, last updated 2026-07-07. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $348,987 in research payments for this study in 2025 (60 payments).

Products named: Epkinly, Imbruvica

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.